|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Title: Phase I/II Trial (Safety and Dosing) of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects: Summary: This study will evaluate in a PH I/II trial in healthy volunteers the safety and tolerability of PVP-I nasal swabs daily application. The intent is to follow with a PH III randomized controlled clinical trial to assess the capacity for PVP-I nasal swabs to mitigate the transmission of respiratory viruses specifically COVID 19.
Description: Safety and tolerability assessment of PVP-I nasal swabs with 5% PVP-I with 0.5% available iodine will be ascertained using weekly measurements of iodine metabolism, thyroid function testing and self reporting of symptoms.Measure: Number of participants with treatment-related adverse events as assessed by self reporting, metabolic and endocrine metrics Time: follow up until 12 weeks
Description: Investigate the dosing of PVP-I nasal swabs twice a day for six weeks with follow up to 12 weeks. The investigators will assess for iodine dose dependent side effects, changes in thyroid functions or iodine clearance.Measure: Number of participants with dose dependent side effects determined by self reporting diaries, thyroid and metabolic testing Time: follow up until 12 weeks